Altamont's Robert Kill Named Intertim CEO at Uroplasty
April 09, 2013
Uroplasty (NASDAQ: UPI), a medical device manufacturer, has announced the appointment of Robert Kill as interim CEO, following the resignation of David B. Kaysen. He will serve while the Board of Directors conducts a search for a permanent CEO. Mr. Kill, who has been a director at the company since 2010, is currently an operating partner with Altamont Capital Partners, a Palo Alto-based private equity firm. He has CEO experience, having served as president and CEO of Virtual Radiologic before joining Altamont.